A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
Status:
Terminated
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with
mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will
positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in
subjects with mild to moderate ALS.